

In the Claims

1. (Currently amended) A ~~fusion partner protein~~ polypeptide of no more than 140 amino acids comprising a choline binding domain of SEQ ID NO:8, wherein a and a heterologous promiscuous T helper epitope from Tetanus toxin is inserted into said SEQ ID NO:8.
2. (Withdrawn) A fusion partner protein according to claim 1 wherein the choline binding domain is derived from the C terminus of LytA.
3. (Withdrawn) A fusion partner protein according to claim 2 wherein the C-LytA or derivatives comprises at least four repeats of any of SEQ ID NO: 1 to 6.
4. (Withdrawn) A fusion partner protein according to claim 1, wherein the choline binding domain is selected from the group of:
 - a) the C-terminal domain of LytA as set forth in SEQ ID NO:7;
 - b) the sequence of SEQ ID NO:8;
 - c) a peptide sequence comprising an amino acid sequence having at least 85% identity to any of SEQ ID NO:1 to 6; and
 - d) a peptide sequence comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:8.
5. (Currently amended) A fusion ~~partner~~ protein comprising a polypeptide as claimed in claim 1 and further comprising a heterologous protein.
6. (Currently amended) A fusion protein as claimed in claim 5 wherein the heterologous protein is chemically conjugated to said polypeptide the fusion partner.

7. (Currently amended) A fusion protein as claimed in claim 5 wherein the heterologous protein is derived from an organism selected from the following group: Human Immunodeficiency virus HIV-1, human herpes simplex viruses, cytomegalovirus, Rotavirus, Epstein Barr virus, Varicella Zoster Virus, hepatitis A virus, hepatitis C virus, hepatitis E virus, ~~from~~ Respiratory Syncytial virus, parainfluenza virus, measles virus, mumps virus, human papilloma viruses, flaviviruses, ~~and~~ Influenza virus, ~~from~~ Neisseria species spp, Moraxella species spp, Bordetella species spp; Mycobacterium species spp, Mycobacterium M. tuberculosis; Escherichia species spp, enterotoxic Escherichia E. coli; Salmonella species spp.; Listeria species spp; Helicobacter species spp; Staphylococcus species spp., Staphylococcus S. aureus, Staphylococcus S. epidermidis; Borrelia species spp; Chlamydia species spp, Chlamydia C. trachomatis, Chlamydia C. pneumoniae; Plasmodium species spp, Plasmodium P. falciparum; Toxoplasma species spp, or Candida species spp.
8. (Currently amended) A fusion protein as claimed in claim 5 wherein the heterologous protein is selected from a tumour associated protein, an immunogenic fragment of a tumor associated protein, a or tissue specific protein, and an or immunogenic fragment of a tissue specific protein thereof.
9. (Currently amended) A fusion protein as claimed in claim 8 wherein the heterologous protein or fragment thereof is selected from MAGE 1, MAGE 3, MAGE 4, PRAME, BAGE, LAGE 1, LAGE 2, SAGE, HAGE, XAGE, PSA, PAP, PSCA, prostein, P501S, HASH2, Cripto, B726, NY-BR1.1, P510, MUC-1, Prostase, STEAP, tyrosinase, telomerase, survivin, CASB616, P53, and or her 2 neu, or an immunogenic fragment thereof.
10. (Previously presented) A fusion protein as claimed in claim 6 further comprising an affinity tag of at least 4 histidine residues.

11. (Currently amended) A nucleic acid sequence encoding a polypeptide protein of claim 1.
12. (Original) An expression vector comprising a nucleic acid sequence of claim 11.
13. (Previously presented) A host cell transformed with an expression vector of claim 12.
14. (Currently amended) An immunogenic composition comprising a fusion protein as claimed in claim 5 claim 1 and a pharmaceutically acceptable excipient.
15. (Original) An immunogenic composition as claimed in claim 14 which additionally comprises a TH-1 inducing adjuvant.
16. (Original) An immunogenic composition as claimed in claim 15 in which the TH-1 inducing adjuvant is selected from the group of adjuvants comprising: 3D-MPL, QS21, a mixture of QS21 and cholesterol, a CpG oligonucleotide or a mixture of two or more said adjuvants.
17. (Previously presented) A process for the preparation of a immunogenic composition, comprising admixing the fusion protein of claim 6 with a suitable adjuvant, diluent or other pharmaceutically acceptable carrier.
18. (Currently amended) A process for producing a polypeptide fusion protein of claim 1 comprising culturing a host cell comprising a vector encoding said polypeptide fusion protein under conditions sufficient for the production of said polypeptide fusion protein and recovering the polypeptide fusion protein from the culture medium.
19. (Currently amended) A pharmaceutical composition comprising a fusion protein fusion protein of claim 5 claim 1.

20.-25. (Canceled)

26. -35. (Withdrawn)

36. (New) A polypeptide according to claim 1 where said T helper epitope is selected from the P2 and P30 epitopes of tetanus toxoid.
37. (New) A polypeptide according to claim 36 consisting of amino acid residues 5-133 of SEQ ID NO:27.
38. (New) A fusion protein comprising a polypeptide of claim 36 and a heterologous protein.